KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 50 filers reported holding KEROS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330 | -19.9% | 10,337 | +0.9% | 0.00% | -100.0% |
| Q2 2023 | $412 | -4.2% | 10,245 | +1.8% | 0.00% | 0.0% |
| Q1 2023 | $430 | -31.4% | 10,067 | -22.9% | 0.00% | 0.0% |
| Q4 2022 | $627 | -99.9% | 13,052 | +3.9% | 0.00% | 0.0% |
| Q3 2022 | $472,000 | +55.3% | 12,559 | +14.0% | 0.00% | – |
| Q2 2022 | $304,000 | -49.3% | 11,014 | -0.2% | 0.00% | -100.0% |
| Q1 2022 | $600,000 | -7.0% | 11,037 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $645,000 | +47.6% | 11,027 | -0.3% | 0.00% | – |
| Q3 2021 | $437,000 | -28.0% | 11,058 | -22.7% | 0.00% | -100.0% |
| Q2 2021 | $607,000 | -17.1% | 14,302 | +20.2% | 0.00% | 0.0% |
| Q1 2021 | $732,000 | -6.5% | 11,900 | +7.2% | 0.00% | 0.0% |
| Q4 2020 | $783,000 | +217.0% | 11,100 | +73.4% | 0.00% | – |
| Q3 2020 | $247,000 | +2.9% | 6,400 | 0.0% | 0.00% | – |
| Q2 2020 | $240,000 | – | 6,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |